Isabelle Buckle

The Institut Pasteur is a private foundation for biomedical research with four core missions of public interest: Research, Education, Public Health, and Valorisation of scientific research via technology transfer and industrial partnerships. The Institut Pasteur is at the heart of the Institut Pasteur International Network, with 32 institutes worldwide linked by the same missions and values.

Achievements/ responsibilities

• Developed and implemented a new strategy for innovation and technological transfer

• 50 people, 50M€ revenues

• 5 departments: - detection of research application; - patent office; - innovation development; -Technology transfer (contract management, licencing, Business development, Spin-off);- Post-contract & alliance management.

Bruker Corporation is a manufacturer of scientific instruments for molecular and materials research, as well as for industrial and applied analysis. Today, worldwide more than 6,000 employees are working on this permanent challenge at over 90 locations on all continents. Bruker systems cover a broad spectrum of applications in all fields of research and development and are used in all industrial production processes for the purpose of ensuring quality and process reliability.

Achievements/ responsibilities

• To propel emerging clinical solutions from point of launch to achieve early, meaningful sales with key opinion-leading customers.

• Assemble all other Bruker Daltonic current and putative clinical solution projects into a phased portfolio plan with resource proposal and gating criteria for successful continuance.

InGen Biosciences, a well-established In Vitro Diagnostics French company. The R&D is mainly focused on the development of multiparametric Biomarkers tests for infectious diseases and oncology. InGen, a 100% Subsidiary, is a French major distribution company for In Vitro diagnostics.

Achievements/ responsibilities

• 70 employees, 3 companies in the group

• Implementation of new vision & strategy

• Development and Implementation of a 5 Years business plan

• Acquisition in 2011 of Gamma, a Belgium company

• Branding & new corporate strategy/communication

• Launch of a our first proprietary IVD Kit

• 2 National consortia for development of a new IVD proprietary product signed

• 7 new distribution partnerships

• 2011 sales turnover 23.5 M€ (+11 . 1%); GM +2%; Net Margin +15.9%; EBITDA +168%; Net income +61%

• Company sold in December 2013